



PRESS RELEASE

Published: 29-12-2023

Inhalation Sciences secures product service contract worth 47,000 Euro

(Stockholm, Sweden, 29 December, 2023) **Inhalation Sciences AB (ISAB) has secured a product service contract with a worth of 47,000 Euro on its instruments at the facilities of a large European pharma company. The order reaffirms the client's strong commitment to its continuing use of ISAB instruments on their robust portfolio of inhaled therapies.**

The client is a long-standing ISAB customer. Its suite of in-house ISAB instruments has played an important role in developing its competitive and substantial pipeline of inhaled therapeutics. The new contract will cover the service and maintenance of their inhouse instruments, ensuring optimal performance.

ISAB CEO Manoush Masarrat: "we're pleased to receive this new order and appreciate the continued trust of our customer. Their long-sighted approach demonstrates their commitment to developing new therapies in an efficient and risk-free way as possible. We look forward to supporting them over the coming years".

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO

E-mail: Manoush.masarrat@inhalation.se

Mobile: +46 (0)73 628 9153

About Inhalation Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company's patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.

The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on 29 December 2023.